Does change in neurotransmitter brain status affect the growth of transplantable melanoma?

Aim. Studying the influence of the features of aminergic brain status on the development of B16/F10 melanoma in mice with urokinase gene knockout and chronic neurogenic pain (CNP).

Material and methods. The study included female (n = 68) С57ВL/6 mice with the normal urokinase gene (+uPA) and C57BL/6-PlautmI.IBug-This Plau6FDhu/GFDhu mice with urokinase gene knockout (–uPA). The model of CNP was created in the animals, and in 14 days B16/F10 melanoma was transplanted. The mice were euthanized 21 days after the transplantation. Levels of adrenaline (A), noradrenaline (NA), dopamine (DA), histamine (H), serotonin (5HT), 5-hydroxyindoleacetic acid (5HIAA) were determined in the brain using standard ELISA test systems (Cusabio, China).

Results. CNP in (+uPA) females resulted in the reduction of almost all studied biogenic amines (BA). On the opposite, (–uPA) females showed an increase in NA, DA, 5HT and a decrease of H. 5HIAA increased in both CNP and gene knockout. 5HT in (+uPA) females with CNP decreased, while its physiological level in gene knockout mice was maintained. After 3 weeks of tumor growth in animals with CNP, (+uPA) mice demonstrated increased levels of studied BA (except for 5HIAA) compared to mice with CNP alone. Only H increase was observed in (–uPA) mice from the similar group.

Conclusion. CNP in mice inhibited A-, NA-, H- and 5HT-ergic systems of the brain; the opposite effects were registered in urokinase gene knockout, except for the H-ergic system. Combination of CNP and melanoma in (+uPA) female mice activated all studied BA systems, and in (–uPA) females – H-ergic system only. Different stressful effects, CNP, and genetic disorders (urokinase gene knockout) contributed to changes in the brain BA system functions, leading to the activation of pro- or antitumor mechanisms.

1. Valiente M., Ahluwalia M.S., Boire A., Brastianos P.K., Goldberg S.B., Lee E.Q., Le Rhun E., Preusser M., Winkler F., Soffietti R. The evolving landscape of brain metastasis. Trends Cancer. 2018; 4 (3): 176–196. DOI: 10.1016/j.trecan.2018.01.003.

2. Jozic I., Stojadinovic O., Kirsner R.S.F., Tomic-Canic M. Skin under the (spot)-light: cross-talk with the central hypothalamic-pituitary-adrenal (HPA). Axis. J. Invest. Dermatol. 2015; 135 (6): 1469–1471. DOI: 10.1038/jid.2015.56.

3. Planken A., Kurvits L., Reimann E., Kadastik-Eerme L., Kingo K, Kõks S., Taba P. Looking beyond the brain to improve the pathogenic understanding of Parkinson’s disease: implications of whole transcriptome profiling of Patients’ skin. BMC Neurol. 2017; 17 (1): 6. DOI: 10.1186/s12883-016-0784-z.

4. Dalvin L.A., Damento G.M., Yawn B.P., Abbott B.A., Hodge D.O., Pulido J.S. Parkinson disease and melanoma: confirming and reexamining an association. Mayo Clin. Proc. 2017; 92 (7): 1070–1079. DOI: 10.1016/j.mayocp.2017.03.014.

5. Xie Q.W., Dai X, Tang X., Chan C.H.Y., Chan C.L.W. Risk of mental disorders in children and adolescents with atopic dermatitis: a systematic review and meta-analysis. Front Psychol. 2019; 10: 1773. DOI: 10.3389/fpsyg.2019.01773.

6. Shukla R.K., Dhuriya Y.K., Chandravanshi L.P., Gupta R., Srivastava P., Pant A.B., Kumar A., Pandey C.M., Siddiqui M.H., Khanna V.K. Influence of immobilization and forced swim stress on the neurotoxicity of lambda-cyhalothrin in rats: еffect on brain biogenic amines and BBB permeability. Neurotoxicology. 2017; 60: 187–196. DOI: 10.1016/j.neuro.2016.07.002.

7. Kusuhara M., Maruyama K., Ishii H., Masuda Y., Sakurai K., Tamai E., Urakami K. A fragrant environment containing α-pinene suppresses tumor gowth in mice by modulating the hypothalamus/sympathetic nerve/leptin axis and immune system. Integr. Cancer Ther. 2019; 18: 1534735419845139. DOI: 10.1177/1534735419845139.

8. Ben-Shaanan T.L., Schiller M., Azulay-Debby H., Korin B., Boshnak N., Koren T., Krot M., Shakya J., Rahat M.A., Hakim F., Rolls A. Modulation of anti-tumor immunity by the brain’s reward system. Nat. Commun. 2018; 9 (1): 2723. DOI: 10.1038/s41467-018-05283-5.

9. Menezes A.C., Carvalheiro M., Ferreira de Oliveira J.M.P., Ascenso A., Oliveira H. Cytotoxic effect of the serotonergic drug 1-(1-Naphthyl)piperazine against melanoma cells. Toxicol. in Vitro. 2018; 47: 72–78. DOI: 10.1016/j.tiv.2017.11.011.

10. Passani M.B., Panula P., Lin J.S. Histamine in the brain. Front Syst. Neurosci. 2014; 8: 64. DOI: 10.3389/fnsys.2014.00064.

11. Hu W., Chen Z. The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmacol. Ther. 2017; 175: 116–132. DOI: 10.1016/j.pharmthera.2017.02.039.

12. Bebe F.N., Hu S., Brown T.L., Tulp O.L. Role, extent, and impact of comorbidity on prognosis and survival in advanced metastatic melanoma: a review. J. Clin. Aesthet. Dermatol. 2019; 12 (1): 16–23.

13. Кит О.И., Франциянц Е.М., Котиева И.М., Каплиева И.В., Трепитаки Л.К., Бандовкина В.А., Розенко Л.Я., Черярина Н.Д., Погорелова Ю.А. Некоторые механизмы повышения злокачественности меланомы на фоне хронической боли у самок мышей. Российский журнал боли. 2017; 2 (53): 14–20.

14. Taylor B.K., Westlund K.N. The noradrenergic locus coeruleus as a chronic pain generator. J Neurosci. Res. 2017; 95 (6): 1336–1346. DOI: 10.1002/jnr.23956.

15. Семина Е.В., Рубина К.А., Степанова В.В., Ткачук В.А. Участие рецептора урокиназы и его эндогенных лигандов в развитии головного мозга и формировании когнитивных функций. Российский физиологический журнал им. И.М. Сеченова. 2016; 102 (8): 881–903.

16. Франциянц Е.М., Каплиева И.В., Сурикова Е.И., Нескубина И.В., Бандовкина В.А., Трепитаки Л.К., Лесовая Н.С., Черярина Н.Д., Погорелова Ю.А. Немашкалова Л.А. Влияние нокаута по гену урокиназы на рост меланомы в эксперименте. Сибирский научный медицинский журнал. 2019; 39 (4): 62–70. DOI: 10.15372/SSMJ20190408.

17. Merino P., Diaz A., Manrique L.G., Cheng L., Yepes M. Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain. J. Biol. Chem. 2018; 293 (24): 9234–9247. DOI: 10.1074/jbc.RA118.002534.

18. Merino P., Diaz A., Jeanneret V., Wu F., Torre E., Cheng L., Yepes M. Urokinase-type plasminogen activator (uPA) binding to the uPA receptor (uPAR) promotes axonal regeneration in the central nervous system. J. Biol. Chem. 2017; 292 (7): 2741–2753. DOI: 10.1074 / jbc.M116.761650.

19. Cao L., Liu X., Lin E.J., Wang C., Choi E.Y., Riban V., Lin B., During M.J. Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell. 2010; 142 (1): 52–64. DOI: 10.1016/j.cell.2010.05.029.

20. Франциянц Е.М., Бандовкина В.А., Погорелова Ю.А., Ткаля Л.Д., Черярина Н.Д. Активность компонентов системы активации плазминогена и некоторых факторов неоангиогенеза в динамике развития перевиваемой меланомы B16/F10. Современные проблемы науки и образования.2015; 5: 617.

21. Cordeiro L.M.S., Rabelo P.C.R, Moraes M.M., Teixeira-Coelho F, Coimbra C.C., Wanner S.P, Soares D.D. Physical exercise-induced fatigue: the role of serotonergic and dopaminergic systems. Braz. J. Med. Biol. Res. 2017; 50 (12): e6432. DOI: 10.1590/1414-431X20176432.

22. Zhu M.Y, Raza M.U., Zhan Y., Fan Y. Norepinephrine upregulates the expression of tyrosine hydroxylase and protects dopaminegic neurons against 6-hydrodopamine toxicity. Neurochem. Int. 2019; 31: 104549. DOI: 10.1016/j.neuint.2019.104549.

23. Urquhart M.A., Ross J.A., Reyes B.A.S., Nitikman M., Thomas S.A., Mackie K., van Bockstaele E.J. Noradrenergic depletion causes sex specific alterations in the endocannabinoid system in the Murine prefrontal cortex. Neurobiol. Stress. 2019; 10: 100164. DOI: 10.1016/j.ynstr.2019.100164.

24. Becker J.B., Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacology. 2019; 4 (1): 166–183. DOI: 10.1038/s41386-018-0125-6.